Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Procept BioRobotics (PRCT) to $55 from $80 and keeps an Overweight rating on the shares. The firm notes the company reported Q2 results with sales that came in line with its preannouncement. Greenfield capital placements were a little light, but management reiterated its outlook for the full year and with a new CEO coming in this quarter, Piper doubts they want to set him up to miss. Overall, guidance was raised in line with the Q2.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- PROCEPT BioRobotics Reports Strong Q2 2025 Growth
- Optimistic Outlook on PROCEPT BioRobotics Amidst Medtech Sector Challenges
- Buy Rating Affirmed for PROCEPT BioRobotics Amid Strategic Leadership and Strong Financial Performance
- PROCEPT BioRobotics Appoints New CEO Larry L. Wood
- PROCEPT BioRobotics: Promising Growth Under New Leadership and Attractive Valuation